In recent years, per- and polyfluoroalkyl substances (PFAS)—often dubbed “forever chemicals”—have drawn intense public and scientific scrutiny due to their extreme environmental persistence and emerging evidence of human health risks. While much attention has focused on PFAS contamination in drinking water, food packaging, and consumer products, a growing area of concern involves their presence—intentional or incidental—in pharmaceuticals, particularly topical medications. This has prompted questions among patients and clinicians alike about the safety profile of fluorinated drugs.
It’s critical to clarify a common misconception: “fluorinated” does not automatically mean “PFAS.” In medicinal chemistry, fluorination—the strategic incorporation of fluorine atoms into drug molecules—is a well-established and beneficial practice. Fluorine enhances pharmacokinetic properties such as membrane permeability, metabolic stability, and oral bioavailability. Widely prescribed agents like levofloxacin (a fluoroquinolone antibiotic) and fluocinonide (a potent topical corticosteroid) contain fluorine as part of their therapeutic design—but they are structurally distinct from PFAS and do not share the same toxicological profile.
True PFAS compounds—characterized by fully fluorinated carbon backbones linked by exceptionally strong carbon–fluorine bonds—are chemically inert and highly resistant to natural degradation. Among them, long-chain variants such as perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) have demonstrated significant bioaccumulation potential and adverse health effects. The International Agency for Research on Cancer (IARC) classifies PFOA as a Group 1 carcinogen (carcinogenic to humans), while PFOS is listed as Group 2B (possibly carcinogenic to humans). Both are regulated under the Stockholm Convention on Persistent Organic Pollutants and appear on China’s “Key Controlled New Pollutants List.”
PFAS exposure in pharmaceutical contexts may arise not only from active pharmaceutical ingredients but also from excipients, manufacturing reagents, or even packaging materials and production equipment. A 2026 study published in Environment International investigated perfluorohexyloctane (F6H8), a compound used in certain ophthalmic and dermatologic formulations. Using human hepatocyte models, researchers detected a metabolite—perfluorohexyloctanoic acid—that exhibits structural and functional similarities to classic PFAS. The findings suggest F6H8 possesses metabolic persistence and may display PFAS-like biological behavior, warranting further investigation into its long-term disposition and toxicity.
For clinicians and patients, evidence-based, context-specific risk assessment remains essential:
First, adherence to prescribing guidelines is paramount. Approved topical fluorinated medications undergo rigorous preclinical and clinical evaluation; regulatory agencies weigh benefit–risk ratios before granting marketing authorization. When used as directed—and under medical supervision—these agents maintain favorable safety profiles for indicated conditions.
Second, risk stratification matters. Long-chain PFAS such as PFOA and PFOS are associated with reproductive toxicity, endocrine disruption, immunosuppression, and increased cancer risk. In contrast, many fluorinated therapeutics lack the carbon-chain length and molecular architecture required for bioaccumulation or persistent biological activity.
Third, special populations—including pregnant individuals, lactating persons, and pediatric patients—often have limited pharmacokinetic and safety data for newer fluorinated agents. Clinical decisions in these groups should be individualized and informed by shared decision-making.
Finally, ongoing surveillance is vital. Toxicological understanding of novel fluorinated compounds continues to evolve through post-marketing studies, real-world evidence, and mechanistic research. Regulatory agencies worldwide are strengthening requirements for environmental and human health assessments of pharmaceutical ingredients—including fluorinated ones—with particular attention to persistence, bioaccumulation, and toxicity (PBT) endpoints.
In summary, the safety of topical fluorinated medications cannot be generalized. Risk depends on molecular structure, route of administration, duration and frequency of use, and cumulative exposure. For currently approved prescription products, short-term use under medical guidance remains supported by available evidence. However, the scientific community maintains a cautious, evidence-driven stance toward long-term implications—especially for compounds exhibiting PFAS-like metabolic behavior. Patients are encouraged to discuss concerns with their healthcare providers and stay informed through authoritative sources as new data emerge.